Michael A. Taylor

Keravision, Inc. was developed medical products for the treatment of common vision problems. The company was developed a new category of non-laser vision correction products for the treatment of common vision disorders, including myopia, hyperopia and astigmatism, to offer an alternative to eyeglasses, contact lenses and other vision correction surgical procedures. Its first product, Intacs corneal ring segments, based on its proprietary patented technology, has been approved by the FDA for correcting mild myopia. Intacs are the first surgical vision correction technology to be approved by the FDA for distribution and sales that is designed to permanently correct a patient's vision while providing the option of removability. Intacs are composed of two thin half-circles of polymer material that are inserted into the periphery of the cornea to reshape the curvature of the cornea to correct vision.